RxDoctor Payments Data

Sonita Singh, MD

Family Medicine · Bethesda, MDNPI 1518953702

Payments from drug & device makers

$1,026in general payments, 2019–2025

Across 44 payments — averaging $23.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$236
  • Amgen$179
  • Actelion Pharmaceuticals US, Inc.$100
  • Lilly USA, LLC$68
  • Pfizer$68
  • Sumitomo Pharma America, Inc.$48
  • plus $328 from 13 others

What the payments were for

  • Food & beverage$1,026100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,026 in reported general payments places this provider in the 65th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$118,730
Medicare patients
287
Services billed
1,614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$55,124
EliquisApixaban19$31,111
MounjaroTirzepatide19$19,564
JanuviaSitagliptin Phosphate11$18,231
OzempicSemaglutide13$17,592
TrulicityDulaglutide12$15,986
Rosuvastatin Calcium238$5,674
SynthroidLevothyroxine Sodium25$2,551
Candesartan Cilexetil22$2,493
Ezetimibe47$2,107
Celecoxib25$1,656
Bupropion XlBupropion Hcl32$1,652
Atorvastatin Calcium117$1,389
Levothyroxine Sodium94$1,005
Tamsulosin Hcl27$830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$68$35,55131 claims
PfizerEliquis$68$31,11119 claims
MerckJanuvia$21$18,23111 claims
Novo NordiskOzempic$236$17,59213 claims
AbbVieSynthroid$41$2,55125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →